Results 31 to 40 of about 582,366 (292)

The coronavirus czar

open access: yesScience, 2020
The COVID-19 pandemic has made German virologist Christian Drosten an unlikely cult figure.
openaire   +3 more sources

Risk factor targeting for vaccine prioritization during the COVID-19 pandemic

open access: yesScientific Reports, 2022
A key public health question during any disease outbreak when limited vaccine is available is who should be prioritized for early vaccination. Most vaccine prioritization analyses only consider variation in risk of infection and death by a single risk ...
Lloyd A. C. Chapman   +8 more
doaj   +1 more source

Protection from infection and reinfection due to the Omicron BA.1 variant in care homes

open access: yesFrontiers in Immunology, 2023
IntroductionFollowing the emergence of SARS-CoV-2 in 2020, care homes were disproportionately impacted by high mortality and morbidity of vulnerable elderly residents.
Saher Choudhry   +10 more
doaj   +1 more source

Clinical features and effectiveness of Chinese medicine in patients with COVID-19 from overseas: A retrospective study in Xiamen, China

open access: yesFrontiers in Public Health, 2022
COVID-19, referred to as new coronary pneumonia, is an acute infectious disease caused by a new type of coronavirus SARS-CoV-2. To evaluate the effect of integrated Chinese medicine and Western medicine in patients with COVID-19 from overseas.
Yu-Xuan Huang   +15 more
doaj   +1 more source

Coronavirus [PDF]

open access: yes, 2013
Name of Virus ...
Franks, Teri J., Galvin, Jeffrey R.
openaire   +1 more source

Coronavirus vaccines

open access: yesVacunas (English Edition), 2020
It is hard to predict when vaccines against infection by SARSCoV-2 coronavirus may become available. The emergence of COVID-19 has led people to think that the best way of preventing it will be by using vaccines, as normally occurs when a new infectious disease appears.
Urbiztondo, L., Borràs, E., Mirada, G.
openaire   +3 more sources

Fluoxetine Can Inhibit SARS-CoV-2 In Vitro

open access: yesMicroorganisms, 2021
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy.
Arthur Dechaumes   +7 more
doaj   +1 more source

The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

open access: yeseLife, 2021
Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the
Gang Ye   +14 more
doaj   +1 more source

An efficient strategy for producing RNA‐free Nucleocapsid protein of SARS‐CoV‐2 for biochemical and structural investigations

open access: yesFEBS Open Bio, EarlyView.
Cleavable N‐terminal Thioredoxin fusion enabled soluble expression and purification of otherwise insoluble SARS‐CoV‐2 Nucleocapsid (N) protein. A four‐step purification strategy yielded highly homogeneous, RNA‐free N protein. Binding assays showed high RNA affinity (Kd ~ 28 nm). The study will facilitate high‐resolution structural studies of N protein,
Shweta Singh, Gagan D. Gupta
wiley   +1 more source

Home - About - Disclaimer - Privacy